TriSalus Life Sciences Received FDA Clearance

The company secured 510(k) approval for its new pressure-enabled drug delivery device, the TriNav Advance.

Updated on Sept. 22, 2026 in Healthcare

Isometric editorial illustration of a surgical microcatheter resting on a sterile clinical surface, representing medical device regulatory approval. — TriSalus Life Sciences received FDA 510(k) clearance for its TriNav Advance microcatheter, a pressure-enabled device designed to treat liver conditions. AI Illustration. Upload story photo >

Live Poll

Do you trust that new medical device innovations make healthcare companies better long-term investments?

TriSalus Life Sciences has received FDA 510(k) clearance for its TriNav Advance, a pressure-enabled drug delivery device designed to support liver-directed therapy. Following the announcement, company shares jumped 26% to reach a price of $6.21.

Why it matters

The device completes the company's portfolio for liver embolization, enabling clinicians to use its specialized microcatheter technology to access small, distal vessels. This regulatory milestone provides the company with a significant clinical tool for liver-directed treatments.

TriSalus Life Sciences saw its stock rise 26% to $6.21 following the news, marking a sharp contrast to its 29% year-to-date decline. The company previously closed at $4.93 on Tuesday before the surge.

The players

TriSalus Life Sciences

This is a medical technology company that develops delivery systems for liver-directed therapies.

Food and Drug Administration

This is the federal regulatory agency responsible for overseeing the safety and efficacy of medical devices in the United States.

The details

The TriNav Advance device utilizes a microcatheter to target small, distal vessels during liver embolization procedures. The product is designed to support a full range of liver-directed therapies by leveraging pressure-enabled delivery.

September 22, 2026: The FDA cleared the TriNav Advance device.
Tuesday, September 22, 2026: The stock closed at $4.93 prior to the surge.
Coming weeks: The company plans a limited market release for the new device.

Market Landscape

This clearance signals a push by TriSalus to consolidate its position in the specialized liver-directed therapy market. By completing its portfolio, the company aims to better compete against established providers of embolization equipment.

The clinical introduction of this device may offer surgeons a new option for precise drug delivery during liver procedures. Investors should note that despite the recent rally, the stock remains down significantly for the year.

The takeaway

FDA regulatory milestones are critical for medical technology firms looking to expand their portfolio and demonstrate clinical viability. The successful clearance provides the company with a clearer path toward commercial expansion in the specialized liver therapy sector.